Hyperlipidemia - PACE-CME

17-22 of 22

The case for early LDL-c lowering in patients at increased CV risk: When should we start?
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
MinuteCE®
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
0.75 program credits
- Pasquale Perrone-Filardi, MD, PhD
0.75 program credits
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
MinuteCE®
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
0.75 program credits
- Ulrich Laufs, MD, PhD
0.75 program credits
MinuteCE®
Innovating the clinical management of LDL-c: Exploring CETP as therapeutic target
0.50 credits 3 episodes
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
- Erin Michos
0.50 credits 3 episodes
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
MinuteCE®
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
0.50 program credits
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
0.50 program credits
CETP inhibition: Lessons from two decades of clinical trials
CETP inhibition: Lessons from two decades of clinical trials
MinuteCE®
CETP inhibition: Lessons from two decades of clinical trials
0.50 program credits
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
0.50 program credits
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
MinuteCE®
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
0.50 program credits
- Erin Michos
0.50 program credits

Previous
1
2
Next

2/2